PRESS RELEASE
News
-
-
PRESS RELEASE
Miracle Cash & More launches PHOENIC, a cutting edge blockchain product to revolutionize tourism industry
Miracle Cash & More has launched PHOENIC, a groundbreaking blockchain product aimed at revolutionizing the tourism industry in Northern Cyprus. This unique technology hotel endeavor intersects luxury tourism with cutting-edge blockchain technology and promises to offer unique opportunities for token holders within the Miracle ecosystem. The project is expected to integrate blockchain concepts into various sectors such as accommodation, food and beverage, and digital identity, thus signaling a new era for tourism in the region. -
PRESS RELEASE
Form 8.3 - The Vanguard Group, Inc.: LondonMetric Property plc
The Vanguard Group, Inc. has disclosed a 5.21% interest in LondonMetric Property plc's 10p ordinary shares, totaling 57,007,801 relevant securities. The disclosure includes details of a recent purchase of 6,924 securities at a price of 1.83 GBP per unit. No supplemental form or attachments are included in this disclosure. -
PRESS RELEASE
Alternative Wellness Health Enters the Hydrogen Water Vertical Market
Alternative Wellness Health, Inc. has announced the launch of a new product, Amethyst HYDRO, for the hydrogen premium water vertical market. The product features a patented hydrogen infusing process with 2.5 PPM and the addition of Fulvic Acid and Aloe Vera, targeting health-conscious consumers. The company aims to capitalize on marketing opportunities and expand its presence in wellness salons, positioning the product as an innovative and healthy energy drink alternative. With a focus on providing great taste and health benefits, the company plans to include CBD and unique flavoring in future products. Alternative Wellness Health, Inc. (EXMT) is a manufacturing and marketing company involved in the sales and marketing of CBD Health products and software applications, aiming to lead in innovative technologies and manufacturing sectors. -
PRESS RELEASE
Core Assets Drills 4.55 Metres of 116g/t Ag, 11.7% Pb+Zn, and 0.41% Cu at the Jackie Target & Exhibits Drilling Core at AME Round Up Conference in Vancouver
Core Assets Corp. presents the assay results from the 2023 shallow drilling campaigns at the Jackie and Grizzly CRD targets in the Silver Lime CRD-Porphyry Project, highlighting significant mineralization across the Silver Lime Project. CEO Nick Rodway comments on the exploration program, emphasizing the multi-deposit potential. The company has been selected to present drill core from the Silver Lime Project at AME Roundup 2024 in Vancouver. The press release provides detailed highlights and discoveries at the Jackie and Grizzly targets, showcasing the potential for important mineral occurrences. The Silver Lime CRD-Porphyry Project, predominantly hosted in carbonate rocks, measures 10KM by 9.5KM with impressive mineralization of various target metals, including silver, copper, zinc, lead, gold, and molybdenum. Further exploration efforts are planned to investigate the geometry and extent of the skarn and carbonate replacement type mineralization continuum at the Silver Lime Project. Core Assets Corp. is a Canadian mineral exploration company focused on the acquisition and development of mineral projects in British Columbia, Canada, with a strong belief in substantial opportunities for new discoveries and development in the Atlin Mining District. -
PRESS RELEASE
Blackwolf Announces DTC Eligibility and Approval to Trade on the OTCQB
Blackwolf Copper and Gold Ltd. is pleased to announce that its common shares are now trading on the OTCQB Venture Market and have received The Depository Trust Company (DTC) eligibility in the United States, allowing for easier trading by US institutional and retail investors. The OTCQB listing and DTC eligibility will enhance the company's visibility and liquidity, providing more opportunities for investors. For more information about the company, investors can visit its OTC Markets profile page. -
PRESS RELEASE
Monogram Orthopaedics to Present at the Canaccord Genuity Musculoskeletal Conference on February 12, 2024
Monogram Orthopaedics Inc., a medical technology company focused on reconstructive joint procedures and surgical robotics, will present at the Canaccord Genuity 2024 Musculoskeletal Conference on February 12, 2024. The presentation will be hosted by CEO Ben Sexson and Chief Financial Officer Noel Knape. Monogram aims to develop patient-optimized orthopedic implants at scale and has a robotic system for high-precision insertion of implants. To learn more, visit www.monogramorthopedics.com. -
PRESS RELEASE
A2Z Secures Initial Purchase Order for 500 Smart Carts in Belgium
A2Z Smart Technologies Corp. announces a significant milestone as Cust2mate Ltd. enters into a purchase agreement for 500 smart carts to be deployed in one of Belgium's largest retail chains, featuring an upfront fee, guaranteed monthly payments, and a revenue-sharing model. CEO Guy Mordoch expresses excitement about the collaboration, highlighting the potential for international market growth and the transformative impact on smart shopping experiences. For more information on A2Z Smart Technologies Corp. and its subsidiary, Cust2mate Ltd., please visit www.a2zas.com. -
PRESS RELEASE
doola Partners With On Deck to Enable Founders Internationally to Go From Idea to Incorporation
doola announces partnership with On Deck to help global entrepreneurs start a U.S. business with support for LLCs, C Corps, and DAO LLCs, including EIN, U.S. address, bank account, and tax filings. This partnership unites two global companies that work with founders to navigate the foundational moments when getting a business off the ground, providing long-term post-formation support for entrepreneurs worldwide. -
PRESS RELEASE
AiCuris and the German Center for Infection Research (DZIF) sign Collaboration and License Option Agreement
AiCuris and the German Center for Infection Research (DZIF) have signed a collaboration and license option agreement to discover new active agents for the treatment and prophylaxis of infections of immunocompromised patients. The partnership aims to develop novel therapies for patients with high medical need. The financial details of the collaboration were not disclosed. For more information, visit www.dzif.de and www.aicuris.com.
